


**Supplementary Figure 1. Cytotoxicity, proliferation and tubulogenesis of Sunitinib and Sorafenib treated PTEC and HMEC.**



**Supplementary Figure 1. Cytotoxicity resistance, proliferation and tubulogenesis of Sunitinib and Sorafenib treated PTEC and HMEC. (A and B):** Cell survival and proliferation of PTEC (black columns) and HMEC (white columns) after 48 h incubation with 1  $\mu$ M Sunitinib or Sorafenib. Sorafenib significantly affected HMEC, but not PTEC. Cytotoxicity was detected as MTT assay, proliferation as BrdU assay. **(C):** Capillary-like organization of PTEC and HMEC. Cells were seeded on Matrigel and observed at different times points. A decrease in tube formation was observed for both PTEC (black columns) and normal HMEC (white columns) after treatment with 2.5  $\mu$ M Sunitinib, while Sorafenib (2.5  $\mu$ M) only affected tubule formation in HMEC. Data are the mean  $\pm$  S.E.M. of a minimum of three independent experiments in triplicate. Statistical significance \*  $p < 0.05$ .